Ditte Rudå

Ditte Rudå serves as a Clinical Associate Professor in the Department of Clinical Medicine at the University of Copenhagen, Denmark, with her institutional address at Blegdamsvej 3, 2200 København N. Her academic role bridges clinical practice and research within the Danish healthcare system through Region H (Copenhagen University Hospital).

Dr. Rudå's research centers on adolescent psychiatry, specifically investigating early-onset psychosis and schizophrenia in youth populations. Her work critically examines antipsychotic pharmacotherapy—including aripiprazole and quetiapine—with emphasis on treatment response predictors, cardiometabolic side effects, cognitive outcomes, and pharmacogenetic factors like CYP2D6 genotyping. She maintains a strong clinical focus on optimizing therapeutic strategies for first-episode psychosis in children and adolescents aged 12-17 years.

Analysis of her 2017-2022 publications reveals consistent leadership in the TEA Trial (Treatment of Early-Onset Adolescent Psychosis), generating high-impact findings on antipsychotic efficacy, metabolic risks, and neurocognitive trajectories. Her collaborative research spans psychiatry, pharmacology, and neuroscience, appearing in top-tier journals such as the Journal of the American Academy of Child and Adolescent Psychiatry and Psychological Medicine. Several publications have received significant media attention, including coverage by news outlets and widespread social media dissemination.